FOR IMMEDIATE RELEASE

Global Media Contacts:

David Schull or Lena Evans
Russo Partners
+1 212-845-4271
+1 212-845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com

David Kujawa
OrbusNeich
+1 954-730-0711 (office)
+1 305-733-7216 (mobile)
dkujawa@orbusneich.com

OrbusNeich’s Genous™ Stent Is a Safe and Effective Alternative for Patients with Contraindications to Drug Eluting Stents (DES)

Review Article Published in the Spring Issue of Cardiology International

HONG KONG, May 11, 2012 – OrbusNeich today announced that data from multiple clinical trials published in the spring issue of Cardiology International demonstrate that the Genous Stent is a safe and efficacious alternative in patients with relative clinical contraindications to the use of DES, as defined by the Guidelines on Myocardial Revascularization.

The review article features clinical trial data from patient subsets including patients whose clinical history is difficult to obtain; patients with poor adherence to dual antiplatelet therapy (DAPT); patients who are scheduled for a non-elective surgery in the short-term, requiring DAPT interruption; patients with an increased risk of bleeding; patients with a known allergy to acetylsalicylic acid, clopidogrel, prasugrel...
or ticagrelor; and patients who need short-term DAPT when undergoing chronic anti-vitamin K treatment.

“In the large, multicenter e-HEALING registry and other clinical studies, the Genous stent has demonstrated good clinical outcomes in real-world use in more than 7,000 patients,” said Sigmund Silber, M.D., Ph.D., of Cardiology Practice and Hospital, Munich, and first author of the publication. “One of the most notable trends is the low incidence of stent thrombosis in even the most complex and highest risk patient populations when accompanied by courses of DAPT significantly shorter than that required for DES and often even with BMS. These data validate the safety and efficacy of the prohealing Genous stent and support its use as an alternative to DES in the challenging patient groups where prolonged DAPT is not an option.”

Al Novak, OrbusNeich’s chairman and CEO said, “Genous is an important technology for patients because it accelerates the natural healing of the vessel wall following stent placement. By helping the body to address the challenge of delayed arterial healing often associated with DES, the Genous Stent reduces the patient’s risk for stent thrombosis.”

The clinical contraindications to the use of DES have been published previously by the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). (Wijns et al., Eur Heart J 2010)

**About the Genous Technology**

Genous is OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent™, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich’s YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

###